FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1853-1855 December 9, 1999 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Pitt, B. PubMed Citation

To the Editor: We would like to call attention to two critical limitations of the Atorvastatin versus Revascularization Treatment (AVERT) study (July 8 issue).¹ First, we take exception to the authors' conclusion that "aggressive lowering of LDL [low-density lipoprotein] cholesterol levels . . . is at least as effective as angioplasty . . . in reducing the incidence of ischemic events in low-risk patients." This statement implies that angioplasty is an effective means of reducing ischemic events in this target population. In fact, the results of previous controlled clinical trials suggest exactly the opposite.^2,3 In the Angioplasty Compared to Medicine . . . [Full Text of this Article]

References

This article has been cited by other articles:

• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]